We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+4.73%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$59.7M
(+5.7%)
Cap. Flow
+$37M
Cap. Flow
% of AUM
3.34%
Top 10 Holdings %
Top 10 Hldgs %
63.03%
Holding
52
New
19
Increased
6
Reduced
15
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$57.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$26.2M |
| 3 |
AKCA
Akcea Therapeutics Inc
AKCA
|
+$22.8M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$20.7M |
| 5 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$55.8M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$25.9M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$20.9M |
| 4 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$17.7M |
| 5 |
Wave Life Sciences
WVE
|
+$16.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.05% |
| 2 | Miscellaneous | 12.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KYNB
1
Kyntra Bio
KYNB
$32.5M
| $123M | 11.04% |
80,690
| – | – |
|
2
Assembly Biosciences
ASMB
$694M
| $109M | 9.85% |
245,264
| – | – |
|
|
3
Ironwood Pharmaceuticals
IRWD
$682M
| $94.9M | 8.55% |
6,139,099
-1,323,488
| -18% | -$20.9M |
|
|
4
Ascendis Pharma A/S
ASND
$16.3B
| $77M | 6.94% |
1,087,257
-376,810
| -26% | -$25.9M |
|
5
Kura Oncology
KURA
$1.13B
| $68.3M | 6.15% |
3,902,975
-1,700
| -0% | -$32.6K |
|
6
Scholar Rock
SRRK
$7.04B
| $61M | 5.49% |
2,367,378
-303,783
| -11% | -$5.58M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $58M | 5.23% |
3,802,327
+841,180
| +28% | +$12.2M |
|
|
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $45.7M | 4.11% |
+837,048
| New | +$57.2M |
|
9
MacroGenics
MGNX
$263M
| $31.8M | 2.86% |
1,481,086
+30,480
| +2% | +$650K |
|
10
Arcus Biosciences
RCUS
$3.72B
| $31.2M | 2.81% |
2,236,387
| – | – |
|
|
KZR
11
DELISTED
Kezar Life Sciences
KZR
| $27.6M | 2.48% |
128,820
+1,600
| +1% | +$279K |
|
|
AKCA
12
DELISTED
Akcea Therapeutics Inc
AKCA
| $26.4M | 2.38% |
+755,120
| New | +$22.8M |
|
|
13
CALL
Ultragenyx Pharmaceutical
RARE
$2.52B
| $24.8M | 2.24% |
+325,000
| New | +$26.4M |
|
14
CALL
Gilead Sciences
GILD
$181B
| $22.6M | 2.04% |
292,600
| – | – |
|
|
15
CRISPR Therapeutics
CRSP
$5.58B
| $22.2M | 2% |
+500,000
| New | +$26.2M |
|
|
KYNB
16
CALL
Kyntra Bio
KYNB
$32.5M
| $21.3M | 1.92% |
14,000
| – | – |
|
17
CALL
Nektar Therapeutics
NKTR
$2.48B
| $19.8M | 1.78% |
+21,667
| New | +$18.5M |
|
|
18
Ultragenyx Pharmaceutical
RARE
$2.52B
| $19.4M | 1.75% |
+254,000
| New | +$20.7M |
|
19
Dianthus Therapeutics
DNTH
$5.92B
| $18.5M | 1.66% |
96,131
| – | – |
|
|
20
CALL
Ascendis Pharma A/S
ASND
$16.3B
| $18.2M | 1.64% |
257,000
-190,000
| -43% | -$13.1M |
|
|
CELG
21
CALL
DELISTED
Celgene Corp
CELG
| $17.9M | 1.61% |
200,000
-385,000
| -66% | -$34M |
|
|
UBX
22
DELISTED
Unity Biotechnology
UBX
| $15.8M | 1.42% |
96,711
-71,353
| -42% | -$11.7M |
|
|
SURF
23
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $14.9M | 1.34% |
1,363,479
+472,671
| +53% | +$5.54M |
|
|
RUBY
24
DELISTED
Rubius Therapeutics, Inc
RUBY
| $14.2M | 1.28% |
+592,128
| New | +$13.5M |
|
|
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $12.5M | 1.12% |
34,650
| – | – |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q3 2018 Portfolio in Review
As of Q3 2018, EcoR1 Capital held 52 positions worth $1.11B, up 5.7% from $1.05B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
EcoR1 Capital deployed $37M of net new capital in Q3 2018, opening 19 new positions and adding to 6 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.9M trimmed.
- EcoR1 Capital's largest Q3 2018 buy was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.
- EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q3 2018, an estimated $12.2M increase.
- EcoR1 Capital's biggest Q3 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.9M.
- EcoR1 Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $55.8M.
- EcoR1 Capital's ten largest holdings make up 63% of its $1.11B portfolio in Q3 2018.
- EcoR1 Capital opened 19 new positions and closed 2 in Q3 2018.
- EcoR1 Capital's portfolio value rose 5.7% quarter-over-quarter to $1.11B.
Based on EcoR1 Capital's 13F filing for Q3 2018, filed 14 Nov 2018.